Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,705.00
Bid: 1,701.00
Ask: 1,701.50
Change: 32.00 (1.91%)
Spread: 0.50 (0.029%)
Open: 1,685.50
High: 1,718.50
Low: 1,673.00
Prev. Close: 1,705.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-Watch the virus' reproduction rate

Mon, 03rd Feb 2020 11:25

* STOXX 600 flat, FTSE 100 up 0.6%
* Ingenico top riser in Europe on Worldline takeover offer
* UK manufacturing ends longest decline since financial crisis

Welcome to the home for real-time coverage of European equity markets brought to you by Reuters
stocks reporters and anchored today by Joice Alves. Reach her on Messenger to share your
thoughts on market moves: joice.alves.thomsonreuters.com@reuters.net



WATCH THE VIRUS' REPRODUCTION RATE (1124 GMT)
A key indicator for stocks owners is the pace by which the coronavirus spreads, Jefferies
analysts wrote in equity strategy note this morning.
Any indication that the reproduction rate is accelerating or decelerating versus a roughly
50% growth rate per day is something worth considering, they argue.
"Presumably, if the rate rises above the line the markets should be more concerned and
vice-versa", they write.
Here's their chart:
(Julien Ponthus)
*****



WHY UTILITIES ARE SO HOT (1037 GMT)
With a nearly 10% relative outperformance so far in 2020 utilities are becoming a
hot spot for investors.
It may be for their defensive qualities and bond-like features that utilities are getting
attention, as virus fears slow economic growth expectations, but it also looks like the
transition to a greener world is going to inject new life into this investment space.
For Barclays, utilities are now a growth sector.
"We believe the EU's and UK's ambitious targets to achieve 'Net Zero' emissions by 2050 are
achievable, placing utilities at the forefront of a 3.7 trillion euro investment boom, and
making the sector a key beneficiary of the coming industrial revolution," the UK bank writes.
Yet the transition is not going to be pain-free and while Barclays sees winners, there will
be losers too.
Among the latter it sees gas distribution infrastructure and power transmission solar
networks, while among the former are renewable generation, power infrastructure, gas
transmission infrastructure and hydrogen.
For more on utilities:
Utilities: flying like a FANG
Davos: Watch those utilities

(Danilo Masoni)
*****


THE CURSED AUTO SECTOR: CORONAVIRUS DENTS PRODUCTION (1015 GMT)
A total of 362 people have succumbed to the deadly virus, leaving the SARS comparison far
behind and businesses worried about supply chain disruptions and falling demand.
Autos, which had a rough 2019, are no exception.
With Wuhan completely shut and the rest of China in extended Lunar New Year holidays, Citi
analysts expect automakerts to take hit with VW being most exposed in terms of production.
Citi sees 40,000 per day reduction in vehicle production in China -- "assuming two weeks of
meaningful impact, this could imply c.1.5-2% drag on annual production and retail sales".
Car parts supplier Valeo and OEMs Daimler and Renault are
seen taking a bigger hit from the output declines. The bank has a "sell" rating on all three of
them.
This chart clearly shows how autos have been dented the most by virus fears:

Autos are clearly becoming the stock market scapegoat of the coronavirus scare here in
Europe. UBS analysts say among the two big underperformers with the biggest exposure to the
epidemic in China, autos are a much bigger concern than luxury stocks.
"On a multi-month view, our Luxury analysts are much more bullish than are our Auto
analysts", UBS writes.
On the big scheme of things, European industrials are holding up, they note.

Another interesting thing is that they are not ready to give up their structurally long
stance on Chine equities.
They do acknowledge however that given the gravity of the situation, they are looking for
"the right hedges".

(Thyagaraju Adinarayan and Julien Ponthus)
*****

THE HARDER THE FALL, THE BIGGER THE BOUNCE (0928 GMT)
It may sound simplistic but in essence that's how many see the opportunity created by the
coronavirus outbreak in China.
Among these is JPMorgan, who believes stocks will make further all-time highs before the
next U.S. recession strikes.
"The Coronavirus outbreak is likely to keep markets under pressure near term. That said, the
more the markets fall in the short term, the more they are likely to rebound once the number of
cases appears to be peaking," strategists at the U.S. bank led by Mislav Matejka say.
"Fundamental backdrop is supportive, in our view, and the fallout from the outbreak is
unlikely to hurt activity prints over the medium term," they add.

(Danilo Masoni)
*****

OPENING SNAPSHOT: INGENICO UP, WORLDLINE DOWN (0834 GMT)
European bourses opened in positive territory with Ingenico as expected topping the Stoxx
600 index after Worldline agreed to buy the French payments company in a deal
which would create a new European champion in the sector.
It is also worth noting that Ingenico shares are trading well below Worldline's 123.1 euro
per share offer price. Worldline shares meanwhile are sliding 5%.
Other top movers in Europe are Siemens Healthineers down 4% and Julius Baer
off 4%, both reported lower profits.
Ryanair shares are jumping 3.6% after company third quarter revenues beat estimates.

(Joice Alves)
****


ON OUR RADAR: UK, DRUGMAKERS, RYANAIR, WORLDLINE (0755 GMT)
Futures point to a higher open in Europe after Brexit and reports on Saturday that Boris
Johnson would consider a looser trade agreement with the European Union, similar to the bloc's
ties with Australia, rather than follow EU rules to reach a closer deal.
Johnson is expected to give a speech on trade today. Traders are also expecting some
eurozone and UK PMI numbers, which will be released this morning.
In terms of single stocks, Siemens Healthineers shares are down 6.5% in early
Frankfurt trade after it said Q1 profit fell on higher diagnostic gear costs
Meantime, UK drugmaker GlaxoSmithKline is also on the radar after it said it is
collaborating with the Coalition for Epidemic Preparedness Innovations to develop a vaccine for
the coronavirus outbreak.
In terms of M&A, traders see payments company Ingenico shares rallying 17% after
Worldline agreed to buy its French peer in a deal which would create a new European
champion in the sector.
Ryanair shares are seen 1-2% higher after 3Q revenues beat estimates but the company
said it may have to push back its long-term target of flying 200 million passengers per year by
as much as two years due to delays in the delivery of Boeing's <BA.N 737> MAX jet.
Some other earning results could move stocks: Swedish telecoms operator Tele2 Q4
earnings beat forecast company launched a new restructuring programme.
Julius Baer is seen 2% lower as it said it will cut 300 jobs after 2019 profit
drop.

Other corporate headlines:
Sri Lanka to probe graft accusations over Airbus deal
Imperial Brands names Stefan Bomhard CEO
(Joice Alves)
*****


EUROPEAN STOCKS SEEN HIGHER (0650 GMT)
European bourses are expected to open higher this morning as investors get some relief from
the fact that the UK left the euro zone ending years of uncertainty around the Brexit outcome.
Fears from Asia will likely put a brake on the enthusiasm. As traders in Asia returned from
a week-long Lunar Year break, shares across the region and global commodity prices stumbled on
concerns that the coronavirus epidemic will hit demand in the world's second-largest economy.
Investors will also have their eyes on PMI data from the euro zone, Germany, France, Italy,
Netherlands and Spain that will be released this morning.
Back in the UK, today's PMI data will likely see little market reaction as services PMI due
Wednesday matters more for the economy.
Financial spreadbetters at IG expect London's FTSE to open 15 points higher at 7,286,
Frankfurt's DAX to open 21 points up at 12,981 and Paris' CAC to open 12 points higher at
5,806.

(Joice Alves)
*****?



(Reporting by Danilo Masoni, Joice Alves, Julien Ponthus and Thyagaraju Adinarayan)

More News
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more
22 Nov 2023 09:48

LONDON BROKER RATINGS: RBC cuts HSBC; Liberum cuts Glencore

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
21 Nov 2023 11:52

GSK to begin phase 3 trials of low-carbon Ventolin inhaler in 2024

(Alliance News) - GSK PLC on Tuesday said it will begin phase 3 trials of a low carbon version of its metered dose inhaler Ventolin using a "next generation" propellant in 2024.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.